Cenkai Shen, Yuxin Du, Shiyu Xiang, Zimeng Li, Chuqiao Liu, Zhiyan Liu, Yijun Wu, Liang Guo, Yan Zhang, Hao Zhang, Chuang Chen, Min Yin, Haitao Tang, Qinghai Ji, Wenjun Wei, Xiao Shi, Yu Wang
{"title":"Revised Perspective on the AJCC Staging System for Medullary Thyroid Cancer: A Study of Two Nationwide Cohorts.","authors":"Cenkai Shen, Yuxin Du, Shiyu Xiang, Zimeng Li, Chuqiao Liu, Zhiyan Liu, Yijun Wu, Liang Guo, Yan Zhang, Hao Zhang, Chuang Chen, Min Yin, Haitao Tang, Qinghai Ji, Wenjun Wei, Xiao Shi, Yu Wang","doi":"10.6004/jnccn.2024.7095","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The current AJCC TNM staging system for medullary thyroid cancer (MTC) is largely adapted from criteria for differentiated thyroid cancer, which may not fully capture MTC-specific prognostic factors. This study aimed to evaluate the prognostic significance of upper mediastinal lymph node metastasis (LNM) and propose corresponding modifications to the N category and staging system to improve their applicability for MTC.</p><p><strong>Methods: </strong>We conducted a population-based, retrospective study enrolling patients with MTC from 19 Chinese referral centers. Demographics and pathologic characteristics were collected, and patients were categorized into 4 LNM subgroups: no LNM, central cervical LNM, lateral cervical LNM, and upper mediastinal (level VII) LNM. We assessed their prognostic significance using Kaplan-Meier survival curves and Cox regression analysis. Recursive partitioning analysis was then applied to regroup patients with similar overall survival (OS). To validate our findings, we analyzed an independent cohort from the SEER database.</p><p><strong>Results: </strong>Our multicenter cohort included 827 patients with initially treated MTC, of whom 438 (53.0%) were female, with a median age of 50 years (IQR, 40-59). Upper mediastinal (level VII) LNM was present in 12.6% of patients and was significantly associated with worse OS, structural recurrence-free survival, and biochemical response compared with other LNM sites (all P<.05). Based on these findings, we proposed up-classifying level VII metastases from N1a to a new category, N1c, while keeping the T and M definitions unchanged. We then regrouped 4 TNM stages: stage I (T1-2N0-1aM0), stage II (T1-3N1bM0, T3N0-1aM0), stage III (T4N0-1bM0, T1-3N1cM0), and stage IV (T4N1cM0, T1-4N0-1cM1). Our modified staging system demonstrated superior prognostic discrimination and predictive power compared with the current AJCC TNM system, both in our multicenter cohort and the SEER validation cohort.</p><p><strong>Conclusions: </strong>For the first time, we identified the upper mediastinum as the most critical site for regional LNM in MTC. Our proposed adjustments to the N category and TNM staging system could provide better risk stratification for patients with MTC, potentially guiding improved clinical management and treatment strategies.</p>","PeriodicalId":17483,"journal":{"name":"Journal of the National Comprehensive Cancer Network","volume":" ","pages":"1-8"},"PeriodicalIF":14.8000,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the National Comprehensive Cancer Network","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.6004/jnccn.2024.7095","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: The current AJCC TNM staging system for medullary thyroid cancer (MTC) is largely adapted from criteria for differentiated thyroid cancer, which may not fully capture MTC-specific prognostic factors. This study aimed to evaluate the prognostic significance of upper mediastinal lymph node metastasis (LNM) and propose corresponding modifications to the N category and staging system to improve their applicability for MTC.
Methods: We conducted a population-based, retrospective study enrolling patients with MTC from 19 Chinese referral centers. Demographics and pathologic characteristics were collected, and patients were categorized into 4 LNM subgroups: no LNM, central cervical LNM, lateral cervical LNM, and upper mediastinal (level VII) LNM. We assessed their prognostic significance using Kaplan-Meier survival curves and Cox regression analysis. Recursive partitioning analysis was then applied to regroup patients with similar overall survival (OS). To validate our findings, we analyzed an independent cohort from the SEER database.
Results: Our multicenter cohort included 827 patients with initially treated MTC, of whom 438 (53.0%) were female, with a median age of 50 years (IQR, 40-59). Upper mediastinal (level VII) LNM was present in 12.6% of patients and was significantly associated with worse OS, structural recurrence-free survival, and biochemical response compared with other LNM sites (all P<.05). Based on these findings, we proposed up-classifying level VII metastases from N1a to a new category, N1c, while keeping the T and M definitions unchanged. We then regrouped 4 TNM stages: stage I (T1-2N0-1aM0), stage II (T1-3N1bM0, T3N0-1aM0), stage III (T4N0-1bM0, T1-3N1cM0), and stage IV (T4N1cM0, T1-4N0-1cM1). Our modified staging system demonstrated superior prognostic discrimination and predictive power compared with the current AJCC TNM system, both in our multicenter cohort and the SEER validation cohort.
Conclusions: For the first time, we identified the upper mediastinum as the most critical site for regional LNM in MTC. Our proposed adjustments to the N category and TNM staging system could provide better risk stratification for patients with MTC, potentially guiding improved clinical management and treatment strategies.
期刊介绍:
JNCCN—Journal of the National Comprehensive Cancer Network is a peer-reviewed medical journal read by over 25,000 oncologists and cancer care professionals nationwide. This indexed publication delivers the latest insights into best clinical practices, oncology health services research, and translational medicine. Notably, JNCCN provides updates on the NCCN Clinical Practice Guidelines in Oncology® (NCCN Guidelines®), review articles elaborating on guideline recommendations, health services research, and case reports that spotlight molecular insights in patient care.
Guided by its vision, JNCCN seeks to advance the mission of NCCN by serving as the primary resource for information on NCCN Guidelines®, innovation in translational medicine, and scientific studies related to oncology health services research. This encompasses quality care and value, bioethics, comparative and cost effectiveness, public policy, and interventional research on supportive care and survivorship.
JNCCN boasts indexing by prominent databases such as MEDLINE/PubMed, Chemical Abstracts, Embase, EmCare, and Scopus, reinforcing its standing as a reputable source for comprehensive information in the field of oncology.